CIRCANOL
Clinical safety rating: caution
Comprehensive clinical and safety monograph for CIRCANOL (CIRCANOL).
CIRCANOL (flupentixol) is a thioxanthene derivative that acts as a dopamine D1/D2 receptor antagonist, with higher affinity for D2 receptors, and also exhibits antagonism at serotonin 5-HT2 receptors. It modulates neurotransmission in the mesolimbic and mesocortical pathways, reducing positive symptoms of schizophrenia and exerting antidepressant effects at low doses via presynaptic dopamine receptor blockade.
| Metabolism | Primarily hepatic via CYP2D6 and CYP3A4, forming metabolites including N-dealkylated and sulfoxide derivatives; undergoes extensive first-pass metabolism. |
| Excretion | Primarily renal (70-90% unchanged) with minor biliary/fecal (5-15%) |
| Half-life | Terminal elimination half-life is 14-18 hours in patients with normal renal function; prolonged in renal impairment. |
| Protein binding | 40-50% bound to albumin and α1-acid glycoprotein |
| Volume of Distribution | 1.2-1.8 L/kg; indicates extensive extravascular distribution, possibly due to tissue binding. |
| Bioavailability | Oral: 60-75% due to first-pass metabolism |
| Onset of Action | Oral: 1-2 hours; Intravenous: immediate |
| Duration of Action | Oral: 6-8 hours; Intravenous: 4-6 hours; duration may be extended in hepatic impairment. |
4 mg orally once daily.
| Dosage form | TABLET |
| Renal impairment | No dose adjustment required for GFR ≥30 mL/min; not recommended for use if GFR <30 mL/min. |
| Liver impairment | Child-Pugh A: no adjustment; Child-Pugh B: reduce dose to 2 mg once daily; Child-Pugh C: not recommended. |
| Pediatric use | Not approved for pediatric use; safety and efficacy not established. |
| Geriatric use | Start at 2 mg orally once daily; increase to 4 mg as tolerated based on response and renal function. |
| 1st trimester | Consult provider |
| 2nd trimester | Consult provider |
| 3rd trimester | Consult provider |
Clinical note
Comprehensive clinical and safety monograph for CIRCANOL (CIRCANOL).
| Breastfeeding | Small amounts excreted into breast milk (M/P ratio approximately 0.3-0.5). Considered compatible with breastfeeding due to limited oral bioavailability in infants; however, monitor infant for sedation or poor feeding. |
| Teratogenic Risk | First trimester: Evidence of human fetal harm based on retrospective studies showing increased risk of congenital anomalies (cardiac defects, neural tube defects) with first-trimester exposure. Second and third trimesters: Risk of fetal hypotension, neonatal respiratory depression, and withdrawal syndrome with chronic use; avoid near term due to risk of premature ductus arteriosus closure. |
■ FDA Black Box Warning
None
| Serious Effects |
Comatose states; CNS depression; severe liver disease; blood dyscrasias; pheochromocytoma; known hypersensitivity to flupentixol or other thioxanthenes; concurrent use with dopamine agonists (except in Parkinson's disease psychosis).
| Precautions | Extrapyramidal symptoms (acute dystonia, akathisia, parkinsonism); tardive dyskinesia with long-term use; neuroleptic malignant syndrome; QT interval prolongation; increased mortality in elderly patients with dementia-related psychosis; seizures; hepatic impairment; hematologic effects (leukopenia, neutropenia); anticholinergic effects; orthostatic hypotension; hyperprolactinemia. |
Loading safety data…
| Fetal Monitoring | Maternal: Blood pressure, heart rate, and signs of hypotension or bradycardia. Fetal: Ultrasound for fetal growth and amniotic fluid volume periodically; nonstress test or biophysical profile in third trimester if indicated. Neonatal: Observe for respiratory depression and withdrawal symptoms after delivery if used near term. |
| Fertility Effects | No significant effect on fertility in animal studies; human data insufficient. May cause transient menstrual irregularities in women of reproductive potential. |